Intermittent Fasting (IF) is fast becoming one of the biggest trends within the health community but it is not a new thing. Humans have been fasting for thousands of years. Some religions such as Christianity, Islam and Buddhism have some form of fasting included. Sometimes it is done out of necessity when there is no food available, for example.
IF is done, as its name implies, intermittently; this means you stop eating for a certain amount of time. It is important to remember that IF is not a pattern of diet but a pattern of eating. There is no calorie counting or changes to your food intake. Instead, you simply change when you eat.
Scheduling your meals is easy as we already “fast” every day when we sleep; we simply extend that fasting period longer than the time we sleep. You do not skip meals at all; you simply rearrange them.
IF doesn’t mean that you do not consume any water during fasting time either. You are allowed to drink tea, coffee and other non-caloric beverages on top of water during your fasting period.
There are many methods of IF that can be done with the most popular being the 16/8 method. This means you fast for 16 hours and eat for 8 hours. Read more about Intermittent Fasting methods here.
M7824 is an investigational immunotherapy thatis designed to bring together both anti-transforming growth factor-β and anti-PD-L1 mechanisms
Data to be presented at ASCO 2018 show M7824‘s anti-tumor activity in patients with advanced non-small cell lung cancer and advanced human papillomavirus associated cancers
M7824continues to be explored in tumors and settings where addressing both mechanisms could leadtoimprovedclinicaloutcomes
Merck, a leading science and technology company, today announced results from expansion cohorts of the ongoing M7824 Phase I clinical trial (NCT02517398) program at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago, June 1-5, 2018. These data include results in patients with advanced non-small cell lung cancer (NSCLC) and in human papillomavirus (HPV) associated cancers (NCT03427411), presented in collaboration with the National Cancer Institute (NCI), providing further evidence that bringing together a transforming growth factor-β (TGF-β) trap with the anti-PD-L1 mechanism may generate clinically relevant anti-tumor activity.
“M7824’s dual approach to fighting cancer, which brings together a TGF-β trap with the anti-PD-L1 mechanism, complements our existing immuno-oncology portfolio,” said Luciano Rossetti, M.D., Global Head of Research & Development at the biopharma business of Merck. “The unique design of this fusion protein offers the potential to optimally engage the TGF-β pathway. This is one example of the creative approaches we are taking to address challenging cancers where we believe we can deliver a transformational change for patients.”
In patients with second line (no prior immunotherapy) advanced NSCLC from the cohort of the ongoing Phase I clinical trial (NCT02517398), signs of clinical activity were seen across PD-L1 expression levels. At the recommended Phase II dose (1200 mg every 2 weeks), an investigator-assessed confirmed overall response rate (ORR) of 40.7% (11/27 patients) was observed in patients with PD-L1+ tumors (≥1%, Ab clone 73-10). In patients with high PD-L1+ expressing tumors (≥80%; Ab clone 73-10 [≥80% as measured with Ab clone 73-10 comparable with tumor proportion score (TPS) ≥50% with 22C3]), ORR was 71.4% (5/7 patients). A median progression-free survival (PFS) of 6.8 months was observed for PD-L1+ patients (1200 mg every 2 weeks) and the median PFS was not reached for the high PD-L1-expressing population owing to the number of patients still responding at the time of analysis. Safety data in this study were consistent with those observed in the overall M7824 Phase I clinical program. The most common treatment-related adverse events (TRAEs) were pruritus (20.0%), maculopapular rash (18.8%) and decreased appetite (12.5%). Grade 3 TRAEs were experienced by 21 patients (26.3%), Grade 4 TRAEs occurred in 2 patients (2.5%). The most common events were skin and subcutaneous tissue disorders. Eight patients (10%) discontinued treatment due to TRAEs.
From the ongoing Phase I, open-label trial NCT03427411 (presented in collaboration with the NCI), signs of tumor burden reduction were seen in 47% (8/17 patients) of patients with advanced HPV associated cancers, including cervical, anal, or head and neck squamous cell carcinoma, enrolled in the dose escalation part of the study. The ORR was 35.3% in patients with HPV associated cancer and 41.7% (including 1 patient with response post-pseudoprogression) in patients with proven HPV-positive disease (12 patients). Safety data in this study were consistent with those observed in the broader M7824 clinical program. A total of 4 patients (23.5%) experienced Grade ≥3 TRAEs, including colitis, cystitis, gastroparesis, pleural effusion and hypokalemia (Grade 4); notably, 3 of these patients had tumor burden reduction. No other Grade 4 or 5 TRAEs were seen.
M7824 is an investigational bifunctional immunotherapy that brings together a TGF-β trap and ‘fuses’ it with the anti-PD-L1 mechanism. M7824 is designed to simultaneously block the two immunosuppressive pathways and control tumor growth by potentially restoring and enhancing anti-tumor responses. M7824 is an important part of a novel combination approach that seeks to harness the power of the immune system and address the tremendously complex nature of difficult-to-treat tumors such as NSCLC and HPV associated cancers. These data build on a number of recent readouts for M7824, including preliminary data in gastric cancer at the ASCO 2018 Gastrointestinal Cancers Symposium. Merck will present data from additional cohorts in hard-to-treat cancer types in the coming year.
In addition to M7824, data from a number of high-priority clinical development programs are also being presented at ASCO 2018, including tepotinib (NSCLC), M2698 (advanced tumors) and two molecules from the DNA Damage Response portfolio (advanced solid tumors).
Merck is committed to exploring an array of targets and taking creative scientific approaches to developing novel therapies for hard-to-treat cancers. With the belief that rational combination is key to the development of potential new and more efficacious treatment options, the company has a particular focus on combination treatment approaches, whether it be with chemotherapy/radiotherapy, other targeted therapies and/or immunotherapies from its own or partners’ portfolios.
M7824 at ASCO
Presentation Date / Time Title Lead Author Abstract # (CDT) Location
M7824 Poster Discussion Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein Sun, Jun 03, targeting PD-L1 Luis G. 11:30 a.m. – and TGF-beta Paz-Ares 9017 12:45 p.m. Arie Crown Theater Oral Presentation Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF- beta, in patients with HPV Sat, Jun 02, associated Julius 5:12 p.m. – 5:24 cancers Strauss 3007 p.m. Hall B1 Poster Session Selection of the recommended Phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting Mon, Jun 04, TGF-beta and Yulia 8:00 a.m. – PD-L1 Vugmeyster 2566 11:30 a.m. Hall A A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resist ant prostate Mon, Jun 04, cancer (mCRPC) 8:00 a.m. – (QuEST1) Jason Redman TPS3130 11:30 a.m. Hall A
About M7824
M7824 is an investigational bifunctional immunotherapy that is designed to bring together a TGF-β trap and ‘fuse’ it with the anti-PD-L1 mechanism. M7824 is designed to simultaneously block the two immunosuppressive pathways – targeting both pathways aims to control tumor growth by potentially restoring and enhancing anti-tumor responses. M7824 is currently in Phase I studies for solid tumors.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of € 15.3 billion in 66 countries.
Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
SAN DANIELE DEL FRIULI, Italy, May 30, 2018 /PRNewswire/ — LimaCorporate is proud to announce that the Revision Stem has achieved 20 years of clinical heritage in the Orthopaedic market. This anniversary consolidates LimaCorporate’s strong position in the Revision hip replacement market, also thanks to the combination with the Delta-One TT and Delta-Revision TT, the first 3D Printed Revision cups featuring LimaCorporate’s proprietary Trabecular Titanium technology. The only technology that boosts over 10 years of clinical heritage in Orthopaedics.
The Revision Stem allows Orthopaedic surgeons to separate the fixation aspect from biomechanics to provide an ideal stem option for a complex Revision situation. The conical stem design with longitudinal fins is designed to achieve a stable stem fixation, followed by the proper placement of the head with the different proximal body options, enhancing a real intraoperative flexibility. The Delta-One TT and Delta-Revision TT acetabular cups apply the same philosophy even to the acetabular side, thanks to the versatility in reconstructing the biomechanics offered by the spacer system, combined with the Trabecular Titanium proven reliability for the implant primary and secondary fixation.
“I started using the Revision Stem due to its simplicity in use and design inspired by the Wagner philosophy, in which a stable implant fixation is achieved through the conical stem profile with finned section. The Revision Stem combines this design with the advantages of the modularity and the wide availability of proximal bodies offered with different heights; its simplicity arises from the combination of different heights of the bodies of the neck with the stem offered with two lengths, allowing to solve the majority of Revision cases, in combination with Delta-One TT and Delta-Revision TT cups,” said Prof. Francesco Benazzo, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
The Revision Stem was fully introduced into the market in 1998, and its design is based on the experience gained by LimaCorporate with the LCR stem, released in 1982. Available in more than 40 countries, the Revision Stem, during these 20 years, continues to represent a valid and solid option for many surgeons dealing with complex Revision surgeries who look for a reliable Revision Stem, supported by several papers published with long term follow-up. The Revision Stem has been used in more than 25,000 surgeries to date.
Most recently, LimaCorporate introduced the Revision Stem odd sizes, enlarging applicability criteria, and improved the Instrument Set layout reflecting the company’s ongoing commitment to deliver innovative, powerful, and robust solutions to Orthopaedic surgeons.
“The excellence of the Italian innovation and technology, combined with the great contribution coming from Orthopaedic surgeons are summarized in our Hip Revision portfolio. LimaCorporate is reconfirming its role in the Orthopaedic market with a special passion for complex cases, becoming the preferred choice for the experts in this field as our 3D Printed technology allows surgeons to address their patients’ needs with a new outlook, including that of custom devices from our ProMade division,” said Luigi Ferrari, CEO of LimaCorporate.
About LimaCorporate
LimaCorporate is a global medical device company providing reconstructive and custom-made Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.
For additional information on the Company, please visit: limacorporate.com
SHANGHAI, June 4, 2018 /PRNewswire/ — Olivier Brandicourt, chief executive officer of the Sanofi Group, recently made a trip to China again. This time, Olivier came to China with the entire Executive Committee of the Group. They kept attending events during the tight five-day schedule, including the 13th International Business Leaders Advisory Council for the Mayor of Beijing, a meeting with the mayor of Shanghai, the signing ceremony for a MOU for strategic cooperation with China Ping An Insurance, visits to hospitals and the Innovation Hub, and multiple exchanges with the China team to get a deeper and more comprehensive understanding of the Chinese market.
Olivier Brandicourt, Sanofi CEO
“Sanofi, as one of the first foreign pharmaceutical companies to enter China, is committed to the idea of innovation, commitment and partnership to bring more high-quality innovative drugs and contribute to Healthy China 2030,” said Olivier. He recently said in an exclusive interview with Xinhuanet that Sanofi will continue to increase investment in China and help establish an Innovated-in-China benchmark in healthcare.
Help build a healthy China with its 36 years of deep roots in China
The 13th International Business Leaders Advisory Council for the Mayor of Beijing was held on May 27. Seventeen advisers from world-renowned international enterprises participated in discussions and made suggestions for the economic and social development of Beijing, focusing on “developing a higher-level open economy” and “improving city construction and management.” Olivier Brandicourt was the only attendee from the pharmaceutical industry.
“The Advisory Council has embodied the goal of open, enterprising and win-win cooperation over the past 40 years in China,” said Olivier. “Back in 1982, when China was in the early stage of reform and opening up, Sanofi came to China. Over the past 36 years, Sanofi China has introduced more than 40 innovative drugs and vaccines, which cover seven of the top 10 diseases causes of death in China. We have continued to bring health and hope to patients.”
According to the Outline of Healthy Beijing 2030, Beijing is committed to providing a “healthy life for everyone, basic health services for everyone and a healthy environment for everyone” and becoming the “No. 1 area of Healthy China” by 2030.
Olivier believes that the following four aspects are crucial for realizing the vision of Healthy Beijing 2030. First, invest in disease prevention. He suggested that residents’ awareness of vaccination should be further enhanced, especially disease prevention for the elderly and patients with chronic diseases. Second, establish a healthcare system featuring primary healthcare. It is suggested that China continue to develop community health centers, improve the cooperation mechanism with grade 3 and first-class hospitals, enhance the clinical diagnosis and treatment capability of general practitioners, and rationally prevent and control chronic diseases. Third, expand the coverage of medical insurance. It is suggested that commercial health insurance be actively developed to build a multi-level medical security system. Finally, develop a healthcare ecosystem that encourages innovation. This includes encouraging doctors to carry out clinical research; empowering the establishment of clinical trial centers; ensuring the quality and efficacy of medicines at the drug development stage; providing policy support; expanding access to medicines; and increasing financial support for high-quality innovative drugs.
Sanofi has three world-class manufacturing plants – based in Beijing, Hangzhou and Shenzhen – that focus on pharmaceuticals and vaccines. In addition, in order to enhance healthcare accessibility, Sanofi became the first multinational healthcare company to set up an independent business unit dedicated to county market in 2011, covering thousands of county hospitals, and launched the Healthy Community Program in 2016 to reach out to thousands of community health centers.
Boost the potential of local innovation with Chinese scientists
2018 marks the 40th anniversary of China’s reform and opening up. China’s economy has shifted from high-speed growth to higher-quality development, and innovation has become one of the main driving forces for the growth of the national economy. Sanofi proposed helping establish an Innovated-in-China benchmark in healthcare. How will Sanofi achieve this goal?
“To drive Created-in-China, we work with Chinese scientists to promote local innovation potential,” said Olivier. Sanofi will continue to increase its R&D investment in China and establish partnerships with more academic institutions. In addition to clinical trials and drug development, Sanofi’s R&D in China will be more involved in early research. In 2008, Sanofi China launched its R&D Center in Shanghai, and the Asia-Pacific R&D hub opened in Shanghai in 2014. The new drugs in the further covers many diseases, such as diabetes, oncology, respiratory diseases, dermopathy and rare diseases. Sanofi and the Shanghai Institutes for Biological Sciences launched an award fund for outstanding young talents. Over 230 outstanding scientific have benefited from the fund over the past 10 years.
In recent years, China has continued to accelerate new drug review and approval, and favorable policies in the pharmaceutical industry have published. Five national departments – including the National Health Commission of the People’s Republic of China – recently formulated and issued the First National List of Rare Diseases, which included 121 rare diseases. On May 22, the Notice on Optimizing the Registration, Examination and Approval of Drugs (No. 23, 2018) was issued by the State Drug Administration and the National Health Commission of the People’s Republic of China. Five new regulations have been put forward to accelerate the approval of innovative drugs, and simplify procedures. More favorable policies have been adopted for R&D and review of rare diseases and the registration of imported products.
“These coming policies are very inspiring for us,” commented Olivier. “It is both a challenge and an opportunity for us to bring innovative and quality drugs to the Chinese market at a faster rate, to accelerate the transformation of more advanced scientific research into reality, and to improve the accessibility of innovative drugs in the current healthcare policy environment.”
“Internet + healthcare” may break the speed limit in clinical trials
Opinions on Promoting the Development of “Internet + Healthcare” was recently issued by the General Office of the State Council. It is aimed at perfecting the “Internet + Healthcare” service system. How will Sanofi embrace the internet?
“Overall, the pharmaceutical industry is slightly slower in accepting digital changes. However, we are catching up fast, both in terms of companies and the industry,” said Olivier. He pointed out that “Internet + healthcare” is a global phenomenon and China is undoubtedly one of the leading countries. Along with the deep integration of biotechnology, gene technology and internet information technology, the healthcare industry can be expected to achieve fast development in the future.
“‘Internet + Healthcare’ is involved in all aspects of healthcare,” said Olivier. “First, techniques such as AI can be used to help doctors make better diagnoses. Patients with diseases such as melanoma and dermatosis can be diagnosed online by photos and artificial intelligence. Second, during treatment, doctors and patients can achieve more interaction with the help of a digital platform to better meet the personalized and diverse needs of patients. Third, from the perspective of the industry, each component – be it new drug research and development, clinical development, market access or promotion – can leverage digital technology and solutions. For example, clinical trials tend to be costly and slow in progress, thus becoming a ‘bottleneck’ in drug development. Digital technology, however, helps to break through bottlenecks. Patients send individual data and medical records to clinicians via mobile phones without leaving their homes. Such a solution can significantly improve the efficiency of clinical trials.” Olivier said that Sanofi is actively engaged in building a digital health infrastructure and working with multiple parties, including China.
Sanofi and Ali Health signed a framework strategic cooperation agreement in 2016, and launched Barcode project in 2017 to guide patients with chronic diseases to achieve safe medication and disease management. By scanning the barcode (drug traceability code) on a medicine box, patients can log on to a safety medication and disease management platform, quickly identify the authenticity of a drug, and obtain information on how to manage their disease better via a mobile phone. The Sanofi China Innovation Hub was recently launched in Shanghai. The first program involves selecting and developing potential e-health programs to speed up digital innovation in healthcare.
“The work on e-health has just begun. There’s a lot of work to be done, and we’re only touching the tip of the iceberg,” said Olivier. “Sanofi sees rapid growth and changes in China. It is an exciting market. Sanofi China achieved 15 percent growth in 2017 and we are expecting three new products to be launched in China in 2018 alone. China is becoming more and more involved in international clinical trail and early stage research, and is becoming a global innovation accelerator.”
Physta® is a patented extract from the Malaysian plant root, Tongkat Ali. The water-soluble extract has been through numerous clinical studies to determine its impact on the human body including, but not limited to, strength, performance and overall health.
Using natural ingredients, the JacSport’s secret weapon is Physta® Tongkat Ali. Whereas most energy drinks come in cans, the drink is available to consumers in easy-to-carry sachets to mix with a recommended 250ml of warm water. The FDA approved pre-workout and recovery drink promises to give more energy and shortens recovery time after a workout.
Some of the studies on the extract have shown that, compared to other extracts of Tongkat Ali, Physta® has proven to support energy and recovery from fatigue, and shown improvement in muscle strength and size in both men and women. It was also shown to maintain normal levels of the stress hormone cortisol and a healthy high levels of testosterone for overall anabolic muscle state during intense endurance exercise tested on mountain bikers.
JacSport is 100% safe with no long-term side effects, this whey-protein-chocolate malt drink is also able to promote blood circulation, and boost a lethargic body and mind.
MOSCOW, May 30, 2018 /PRNewswire/ — Recently, China-Russia Nutrition Forum was successfully held in Moscow, taking “World Digestive Health Day” as the theme. The forum was jointly held by Chinese Nutrition Society (CNS), the Federal Research Centre of Nutrition, Biotechnology and Food Safety, Russia (FRC) and in corporation with Mengniu Danone Joint Venture. This is the first time China and Russia have an official exchange on nutrition issues, reaching consensus in the importance of consumer education of active probiotic diary drinks. Based on their academic interaction, CNS and FRC signed a Memorandum of Understanding on strategic cooperation. They have a common goal to jointly enhance collaboration in the field of nutrition and health and boost talent sourcing in dairy technology. To achieve this, they will facilitate bilateral trade processes and dairy industry development by providing guidance and support for laws and regulations for seamless trade in dairy products in both countries.
Representatives of Nutrition Society of China and Russia at the MoU signing.
As the society’s overall consumption upgrades, health education matters more than material gains. Yang Yuexin, CNS Director commented, “Chinese people are having substandard daily intake of dairy, especially active probiotic drinks. To educate the public the health benefits of active probiotic is very important.”
CNS Director Yang Yuexin delivers a speech.
There is a similar situation in regard to active probiotic drinks in Russia. “The dietary structure of Europe is mainly made up of meat, egg and dairy. Russians have dairy consumption meeting guiding criterion, but low awareness of the function of active probiotic drinks which need to be greatly improved,” expressed by Sheveleva Svetlana, Head of the Laboratory of Biosafety and Analysis of Nutrimicrobioman, the Federal Research Centre of Nutrition and Biotechnology, Doctor of Technical Sciences.
Sheveleva Svetlana, Head of the Laboratory of Biosafety and Analysis of Nutrimicrobioman, the Federal Research Centre of Nutrition and Biotechnology, Doctor of Technical Sciences speaks at the event.
Under such condition, Mengniu, one of the leading Chinese brands, has promoted the international exchange and consumer education in dairy industry. Mengniu and Danone have joined hands in the field of fresh yogurt to focus on bringing in Danone’s high-quality bacteria, making full use of global R&D capability, and benchmarking leading international production technology and quality management system. They aim at the future where Chinese consumers can enjoy quality products based on the principle of “same production line, same quality and same standard” with European and global counterparts.
WASHINGTON, May 30, 2018 /PRNewswire/ — Avant Diagnostics, Inc. (“Avant”) (OTC: AVDX), an oncology-focused healthcare data-generating solutions company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced that it has entered into securities purchase agreements with accredited investors pursuant to which the Company sold 650,000 shares of the Company’s newly designated Series A Preferred Stock (the “Series A Preferred Stock”) for aggregate gross proceeds of $650,000. The Series A Preferred Stock will control a majority of the voting power of the Company. Upon consummation of a reverse stock split of the Company’s common stock, resulting in approximately 15,000,000 shares of the Company’s common stock outstanding, the investors shall subsequently take all necessary steps with the Company to convert all outstanding shares of the Series A Preferred Stock into shares of the Company’s common stock.
In connection with the closing, Jeffrey Busch was appointed as Chairman of the Board of Directors (the “Board”), John Brugmann was appointed as a Director on the Board, and Mick Ruxin, M.D., joined the Company as President & Chief Executive Officer, and a Board Member. Certain current investors and the new investors in the offering will collectively have the right to appoint 9 total directors to the Board.
Concurrently with the private placement, certain existing debtholders of the Company exchanged an aggregate of $1,824,856 currently due and payable under existing indebtedness for (i) an aggregate of 516,155 shares of Series A Preferred Stock (ii) approximately 26,000,000 shares of series B preferred stock (the “Series B Preferred Stock”) and (iii) new notes for an aggregate principal amount of $265,091. In addition, certain existing debtholders of the Company who participated in private placements or exchanges during the year ended December 31, 2017 waived all of the future rights under their financing documents as well as their security interests in the Company’s assets. Upon filing an amendment to the Company’s articles of incorporation to increase the number of shares of authorized common stock (the “Amendment”) so that there is an adequate amount of shares of authorized common stock for issuance upon conversion of the Series B Preferred Stock, each share of Series B Preferred Stock will be automatically converted into ten (10) shares of common stock of the Company, subject to adjustment.
The following summary of the terms of the securities described above does not purport to be complete and is qualified in its entirety by the transaction documents filed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 25, 2018.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Avant Diagnostics, Inc. Avant is a healthcare data-generating solutions company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology. Avant provides personalized medicine data generating capabilities through its TheraLink® assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across multiple cancer types, including breast, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies.
Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Avant’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our products will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant’s Form 10-K filed with the Securities and Exchange Commission on January 13, 2016, and other periodic reports filed with the Securities and Exchange Commission.
Investor and Media Contact: Scott VanderMeer Interim CFO Phone number: 708-710-9200 Email: scottv@avantdiagnostics.com
BALTIMORE, May 30, 2018 /PRNewswire/ — Cancer is said to be a disease of death. Once a person has cancer, it is like being sentenced to “death with reprieve.” The remaining days are few. For long, human beings have been conducting research to overcome cancer. Recently, the team led by Dr. Zhang Chunyu, an American Chinese scientist and the founder of SanuLife Inc, has made a major breakthrough and discovered a novel transcriptional activation pathway that can restore the expression of a tumor suppressor protein that combines both anti-cancer and anti-aging effects in cancer cells and normal cells. Based on the research results the team produced a dietary supplement for the benefit of mankind.
An American Chinese Scientist Brings Major Discoveries of Cancer Prevention and Anti-aging Research
According to the World Cancer Report released by the World Health Organization, cancer is the second leading cause of death in the world, while 40% of cancers are preventable. “The biggest risk factor for cancer is age,” Zhang Chunyu pointed out.
With the development of science and technology and the advancement of medical care, the average life expectancy of human beings has increased year by year. The aging of the population has become increasingly serious, coupled with the modern sedentary lifestyle, high-intensity work pressure, unhealthy eating habits, unsatisfactory living environment and other factors. These challenges have accelerated the decline of human physical function, and various types of chronic diseases, especially the incidence of cancer remains high. How to scientifically prolong healthy lifespan and improve quality of life has become the most pressing research topic of the moment.
Dr. Zhang Chunyu, Principal Investigator, Lung Cancer and Aging Program, the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
As Principal Investigator of the Lung Cancer and Aging Program at the Sidney Kimmel Comprehensive Cancer Center of the Hopkins University School of Medicine, Dr. Zhang Chunyu has worked at Yale, Harvard, National Cancer Institute, Lovelace Respiratory Research Institute and other top-notch universities and research institutes in the United States. He has produced a number of internationally leading research results in the fields of “Clock of Life” telomere and telomerase; Werner premature aging protein and DNA polymerase; nuclear encoded mitochondrial longevity mutant protein; aging-associated chronic inflammation, obesity and cancer biomarker FAT10; immunoregulatory factor gene expression and tissue localization; the key signal pathway of PI3K/Akt/mTOR for cancer and aging and its inhibitors; gene expression changes during lung cancer progression and chemotherapy resistance and prognosis survival; DNA damage from cigarette smoking extracts on airway epithelial cells; molecular mechanism of NOXA on pulmonary inflammation remission, etc.. Relevant articles have been published in the international top journals and core specialized magazines, including Cell, Proceedings of the National Academy of Sciences and Nature publications.
Dr. Zhang Chunyu and his team studied the expression and function of the tumor suppressor gene RhoB to prove that it plays an important role in maintaining the normal morphology and function of the respiratory system at the protein level. For the first time, they discovered that in the process of cancer evolution and aging, the signaling pathways and molecular mechanisms of efficient transcriptional activation of the tumor suppressor gene RhoB, which are down-regulated by various epigenetic mechanisms, have led to the construction of a unique dual-luciferase single vector in the world. The research team also, established a high-throughput drug screening system, and animal models for real-time monitoring anti-tumor drug response. In addition, the team also used the system to screen out several novel anti-cancer small molecules from the National Cancer Institute’s Diversity Library, and one of the compounds continuously and efficiently induces protein expression of the tumor suppressor gene RhoB in various cancer cells such as lung cancer, brain tumor, and rhabdomyosarcoma, and inhibits cancer cell proliferation, migration and induces apoptosis, without too much cytotoxicity.
Based on this discovery, Dr. Zhang Chunyu scientifically allocated small molecule nutrients of plant to protect normal cells and prolong their lifespan while inhibiting cancer cells proliferation, migration, and causing them apoptosis. This leading scientific research proves that dietary intervention can not only effectively inhibit skin inflammation, delay skin aging, but also significantly reduce the occurrence and development of lung cancer induced by tobacco carcinogens.
A New Dietary Supplement of Anti-cancer Rejuvenation to Benefit Mankind
Based on the above research results, Dr. Zhang Chunyu and his team successfully developed a dietary supplement containing key components of Ceramide, Curcumin, and EGCG, and submitted applications for related patents to the U.S. Patent and Trademark Office. At the same time, in order to speed up the transformation of results, Dr. Zhang Chunyu established SanuLife Inc in Maryland, USA. Focusing on research and development of science-based biopharmaceuticals and products boosting health management and self-cultivation performance, SanuLife aims to integrate high-quality resources and forward-looking technologies to provide one-stop, customized and intelligent health services that precisely address the physical and mental needs of users.
The ROVIDIUM series products of SanuLife Inc are scientific, safe, and effective dietary supplements that extract natural components in plants and harness the down-regulated RhoB during transformation from normal cells to cancer cells. ROVIDIUM also gives play to the synergy between RhoB with longevity transcriptional factor Nrf2, which drives expression of endogenous antioxidant, anti-inflammatory and anti-fibrotic genes, through another tumor suppressor gene p21 induced by RhoB. The products restore endogenous RhoB expression, which is continuously observed to be epigenetically down-regulated during pulmonary aging, skeletal muscle decline, and tumorigenesis, and activate Nrf2 through p21 to stabilize the genome and protect cells from carcinogenesis, which aims to help delay aging, prevent cancer and increase healthspan.
POMEZIA, Italy, June 1, 2018 /PRNewswire/ — Menarini Ricerche (Menarini Group) will present at ASCO Annual Meeting 2018 the study design of CD205-Shuttle, a multicenter first-in-human clinical study to evaluate MEN1309/OBT076, an antibody drug conjugate (ADC) investigated for the treatment of metastatic solid tumors and non-Hodgkin’s lymphoma (NHL).
MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody, in co-development with Oxford BioTherapeutics (OBT), conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein CD205/Ly75, that is over-expressed in several solid tumors and NHL.
The poster “CD205-Shuttle study: A first-in-human trial of MEN1309/OBT076 an ADC targeting CD205 in solid tumor and NHL” focused on the innovative design of the dose-escalation study will be presented during the session “Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics” Abstract no. TPS2606, on June 4, 2018 between 8:00 AM-11:30 AM at the McCormick Place Convention Center in Chicago, Illinois.
The CD205-Shuttle study is ongoing in major European oncology centers in Italy, Spain, Belgium and the UK. The study investigated to date 5 dose levels. The sixth dose level is currently being evaluated.
About the Menarini Group
The Menarini Group, with its headquarters in Florence, is present in 136 countries around the world with 17,000 employees. With a turnover of 3.6 billion Euro, Menarini today is 13th in Europe out of 5,345 companies and 35th worldwide out of 21,587 (source: IQVIA). Menarini has 6 Research & Development centres and its products are present in the most important therapeutic areas including cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesics. Menarini’s products are manufactured in the Group’s 16 production sites, in Italy and abroad, where more than 583 million packs are produced and distributed over five continents each year. Through its pharmaceutical products, Menarini contributes continuously and with the highest quality standards towards the health of patients all around the world.
The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini, is developing four investigational new oncological drugs. Two of them are biologics, namely the anti-CD157 antibody MEN1112, and the toxin-conjugated, anti-CD205 antibody MEN1309. In addition, Menarini has recently added two small molecules to its oncology pipeline, the dual PIM and FLT3 kinase inhibitor MEN1703, and the PI3K inhibitor MEN1611, in clinical development for the treatment of a variety of hematological and/or solid tumors.
SHANGHAI, June 1, 2018 /PRNewswire/ –The 13th China International Exhibition of Senior Care, Rehabilitation Medicine & Healthcare, also known as CHINA AID, will be held from June 13 to 15, 2018 at the Shanghai New International Expo Centre and is organized by Shanghai INTEX Exhibition Co., Ltd.
CHINA AID is the leading exhibition and conference event for the burgeoning senior and long-term care market in China, its reputation now firmly established as the most authoritative industry trade show in the country. Taking place annually in Shanghai, the show offers an unparalleled opportunity to meet with prospective clients and customers, partners and distributers from across China.
Boasting a floor space exceeding 25,000sqm and an attendance of over 40,000 visitors in 2017, exhibitors are brought together within six category areas of exhibiting space, showcasing their services, products and technology in Rehabilitation Medicine, Healthcare Management, Senior Care, Nursing Care, Assistive Devices, and Age-friendly Housing.
CHINA AID features some of the most innovative and established elderly and long-term care industry leading enterprises, offering broad coverage across the full spectrum of our category areas. Long-standing exhibitors of note include TOTO, Panasonic, Tarkett, Legrand, Dewert, Ottobock, Francebed, Paramount, Schtaf, Yonger, Toyota, Honda, Taiping Community and Baosteel. Together with other mainstay brands they form the exhibition’s backbone, through which thousands of elderly and long-term care products, technologies and services are displayed, demonstrated and presented.
By maintaining a strong focus on the invaluable societal benefits of care whilst enabling a pioneering market role in its delivery, CHINA AID provides a mufti-functional events platform for companies, organizations and associations that serve the elderly and disabled. By acting as a fully engaged hub and connector for the industry, CHINA AID fulfills this role effectively through organizing influential conferences and other events for knowledge exchange, arranging interactive demonstrations and tours, facilitating networking and international match-making sessions, and by creating the space to foster vibrant business opportunities and strategic partnership development.
Professional business forums and industry match-making sessions are held annually alongside the main exhibition, which include the China International Forum on Ageing, the China Forum for Senior Care Institutions, the China Forum on Gerontological Health & Social Work, the Symposium on Dementia Quality Care, the Sino-Japanese Silver Industry Match-making Forum, the 6th China Design Competition for Welfare Products Awards Ceremony, the Industry Movers Forum and more.
This year, we are proud to announce the debut of the Senior Care Industry Leaders’ Summit, which will be held on Tuesday June 12th 2018, the day before the opening of the exhibition. Leaders from national departments and agencies, as well as from the Shanghai municipal government and many other provinces have been invited to participate and deliver insightful speeches on how they see the future of senior care developing in China. Widely respected experts and eminent scholars, both foreign and domestic, will exchange research findings on aspects of senior care, assistive technology, rehabilitation medicine and more.
CHINA AID is not only a celebration of independent living, caring for disadvantaged groups and social development, but also an essential platform for the sharing of experience and the exchange of information for those involved in the provision of senior and long-term care products and services.
